Gigazine [14 April 2018]

“高価な「C型肝炎治療薬」の効果を保ったまま安価で提供するための取り組みが進行中” – “Efforts to provide low cost while maintaining efficacy of ‘expensive hepatitis C treatment’ is ongoing”

Click here to read the article

New affordable hepatitis C combination treatment shows 97% cure rate

Paris – 12 April 2018
Results support a public health approach to hepatitis C
An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard-to-treat cases, according to interim results from the Phase II/III STORM-C-1 trial presented by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) at the International Liver Conference in Paris.